What’s Going On With AMD Stock Thursday?

AMD stock gained 42% in last six months, winning 33% market share in server CPUs. Analysts see potential in upcoming products.

Advanced Micro Devices, Inc (NASDAQ:AMD) stock gained over 42% in the last six months.

Analysts tout AMD as the second most significant beneficiary after Nvidia Corp (NASDAQ:NVDA). AMD recently highlighted gaining a 33% market share in the server CPU market in the first-quarter, up from ~8% in 2020.

After the Taiwan event, analysts called out AMD’s pipeline, including the upcoming MI325, MI350, MI400, and MI400.

Recent reports indicated AMD’s plans to tap Samsung Electronics Co to develop 3-nanometer chip processing technology. However, TF International Securities analyst Ming-Chi Kuo stated there is a lack of progress between the companies. In her latest post, the analyst further noted that by the time the companies are ready to commercialize the 3-nm chip technology, Taiwan Semiconductor Manufacturing Co’s (NYSE:TSM) 2-nm will already be in mass production. According to the analyst, it would make more sense for AMD to invest in TSMC’s 2-nm products.

According to the analyst, AMD and Samsung are currently discussing leveraging 5-nm for AMD’s AI chip MI400 series.

AMD’s market cap of $269 billion trails the undisputed numero uno AI beneficiary Nvidia’s market cap of over $3 trillion, with the latter crossing Apple Inc’s (NASDAQ:AAPL) market cap this Wednesday.

Investors can gain exposure to AMD via iShares Core S&P 500 ETF (NYSE:VOO).

Price Action: AMD shares traded higher by 0.28% at $166.64 premarket at the last check Thursday.

Now Read: Jensen Huang’s Nvidia To Remain ‘Top Dog’ In AI Chip Battle, AMD To Get A Slice, Predicts Tech Investor Paul Meeks

Total
0
Shares
Related Posts
Read More

Immutep Earlier Announced Final Data in 2 nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

– Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announces positive final data from Part B of the TACTI-002 Phase II trial in 2 nd line metastatic non-small cell lung cancer (NSCLC) patients refractory to anti-PD-(L)1 therapy via a Mini Oral presentation at ESMO's European Lung Cancer Congress (ELCC) 2023.

IMMP